A phase 3 trial showed that alpelisib plus olaparib did not reduce the risk of progression or death in relapsed/refractory ...

A promising allogeneic CAR-T therapy has shown the potential to succeed in ovarian cancer where standard CAR-T treatments ...

New analysis reveals enzalutamide significantly outperforms darolutamide in treating metastatic hormone-sensitive prostate ...

Trifluridine/tipiracil shows potential in improving disease-free survival in colorectal cancer patients post-surgery, despite ...

New research reveals that many patients with low-risk thyroid cancer can safely skip postoperative radioiodine ablation, ...

Brexu-cel demonstrated efficacy and safety even in patients with B-cell acute lymphoblastic leukemia with central nervous ...

A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

The results support the potential for treatment de-escalation after hysterectomy for women with early-stage, ...

A multidisciplinary expert panel issued recommendations on the use of bronchoscopic biopsies in terms of safety and sample ...

Manero, MD, discusses findings from the phase 3 COMMANDS trial evaluating luspatercept in patients with myelodysplastic ...

New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic ...